Free Trial

Leerink Partnrs Has Bullish Estimate for DGX FY2025 Earnings

Quest Diagnostics logo with Medical background

Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Investment analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Quest Diagnostics in a note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $9.73 for the year, up from their prior forecast of $9.72. The consensus estimate for Quest Diagnostics' current full-year earnings is $9.70 per share. Leerink Partnrs also issued estimates for Quest Diagnostics' FY2026 earnings at $10.65 EPS, FY2027 earnings at $11.59 EPS and FY2028 earnings at $12.69 EPS.

DGX has been the topic of a number of other research reports. Redburn Partners set a $195.00 target price on Quest Diagnostics in a research report on Wednesday, April 2nd. Mizuho lifted their price target on shares of Quest Diagnostics from $178.00 to $189.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Wall Street Zen lowered shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Truist Financial lifted their price target on shares of Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday, April 23rd. Finally, Barclays lifted their price target on shares of Quest Diagnostics from $175.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 23rd. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of "Moderate Buy" and an average target price of $185.73.

View Our Latest Analysis on Quest Diagnostics

Quest Diagnostics Stock Down 1.2%

Shares of NYSE:DGX traded down $2.13 during midday trading on Wednesday, reaching $171.49. 914,056 shares of the company were exchanged, compared to its average volume of 993,313. The stock has a fifty day simple moving average of $176.19 and a two-hundred day simple moving average of $168.20. Quest Diagnostics has a fifty-two week low of $137.71 and a fifty-two week high of $182.38. The firm has a market cap of $19.15 billion, a PE ratio of 21.68, a P/E/G ratio of 2.42 and a beta of 0.49. The company has a quick ratio of 1.31, a current ratio of 1.44 and a debt-to-equity ratio of 0.84.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, topping analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bruce G. Allen Investments LLC increased its position in Quest Diagnostics by 57.8% during the 1st quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company's stock worth $31,000 after buying an additional 67 shares during the period. First Horizon Advisors Inc. increased its position in Quest Diagnostics by 76.6% during the 1st quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company's stock worth $32,000 after buying an additional 82 shares during the period. Golden State Wealth Management LLC increased its holdings in shares of Quest Diagnostics by 157.3% during the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock worth $33,000 after purchasing an additional 118 shares during the period. NBC Securities Inc. bought a new position in shares of Quest Diagnostics during the first quarter worth approximately $35,000. Finally, Continuum Advisory LLC increased its holdings in shares of Quest Diagnostics by 11,100.0% during the first quarter. Continuum Advisory LLC now owns 224 shares of the medical research company's stock worth $38,000 after purchasing an additional 222 shares during the period. 88.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Mark E. Delaney sold 874 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $175.72, for a total value of $153,579.28. Following the sale, the senior vice president owned 8,372 shares in the company, valued at approximately $1,471,127.84. This represents a 9.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.16% of the company's stock.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Investors of record on Monday, July 7th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date is Monday, July 7th. Quest Diagnostics's dividend payout ratio (DPR) is presently 40.46%.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Should You Invest $1,000 in Quest Diagnostics Right Now?

Before you consider Quest Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.

While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines